Israel Biotech Fund — Full Portfolio
19 tracked investments · listed companies and verified rows first
Champions Oncology offers a KRAS-focused preclinical platform built on patient-derived xenograft (PDX) models screened with the pan-RAS(ON) inhibitor daraxonrasib, combining in vivo pharmacology with multi-omic characterization to study drug response and resistance.
AI & Machine LearningBiotechHealthtechHackensack, US
Ronnie Morris(Executive Officer, Director)inRonnie Morris, M.D.(Executive Officer, Director)inJames McGorry(Executive Officer)David Miller(Chief Financial Officer)inJoel Ackerman(Executive Officer, Director)inRob Brainin(Chief Executive Officer)in
Board seatDavid Sidransky· per SEC Form D · $14M raise · filed Mar 2015
Co-investorsBattery VenturesNew Enterprise Associates (NEA)
Galmed is a pharmaceutical company developing metabolic and inflammatory therapeutic drugs through discovery and clinical trial phases.
BiotechTel Aviv
Allen Baharaff(Executive Officer, Director)Tali Gorfine(Executive Officer)Yohai Stenzler(Executive Officer)inLiat Hayardeny(Executive Officer)in
BoardChaim Hurvitz(Director)
Board seatDavid Sidransky· per SEC Form D · $350K raise · filed Aug 2017
MediWound is a biotechnology company developing enzymatic treatments that selectively remove eschar tissue while preserving healthy tissue for burns and chronic wounds.
BiotechHealthtechMedical DevicesYavne
Boaz Gur-Lavie(Chief Financial Officer)Sharon Malka(Director)Ety Klinger(Executive Officer, Director)inTzvi Palash(Executive Officer)Assaf Segal(Director)Sharon Kochan(Director)
Co-investorsClal Biotechnology IndustriesDeep InsightGandyr InvestmentsNew Era Capital PartnersPoint72 Ventures
AION Labs is a venture studio founded by pharmaceutical companies (AstraZeneca, Pfizer, Merck, Teva) alongside AWS and venture capital partners to build and scale companies applying AI and emerging technologies to drug discovery and development.
AI & Machine LearningBiotechDeep Tech
Dr. Yuval Cabily(Co-Founder & Managing Partner)Ido Zairi(Co-founder & Managing Partner)in
Co-investorsAmiti Ventures
Anser Bio is a biotech company focused on cancer research and drug development, working on areas such as exosome-based therapeutics, protein purification, and cell technologies.
BiotechDeep TechHealthtechMedical Devices
Lana Volokh(Co-founder)Alex Tendler(Co-founder)Yevgeny Tendler(CSO)
Co-investorsPeregrine Ventures
Vensica is a clinical-stage medical company developing ViXe, a needle-free treatment for overactive bladder that combines the neurotoxin Xeomin with Vibe, an ultrasound-based drug delivery device that microinjects medication into the bladder wall.
BiotechHealthtechMedical Devices
Avner Geva(CEO, Co-founder)inAvi Eftel(CTO, Co-founder)inRoger R. Dmochowski(CMO)Ken Berlin(Executive Chairman)in
Co-investorsTrendlines Group
Orgenesis provides decentralized manufacturing infrastructure for cell and gene therapies, enabling on-site processing of CGTs in regional centers through its POCare™ platform and OMPUL™ mobile processing units.
Advanced ManufacturingBiotechHealthtechMedical DevicesGermantown, US
Neil Reithinger(Executive Officer)inVered Caplan(Executive Officer, Director)inFerber Ferber(Executive Officer)Joseph Tenne(Executive Officer)inSarah Ferber(Executive Officer)
Board seatDavid Sidransky· per SEC Form D · $10M raise · filed Dec 2015
BiotechSan Diego, US
Jamie Sulley(Executive Officer, Director)Joanne Barsa(Executive Officer)
BoardFred Knoll(Director)David Sidrandky(Director)Patrick Ostronick(Director)
Board seatDavid Sidransky· per SEC Form D · $800K raise · filed Sep 2015
4C Biomed develops an immunological screening platform to identify drug targets for cancer immunotherapy development.
AI & Machine LearningBiotechDigital HealthHealthtechTel Aviv, IL
Anthony Angel(Chairman & Co-founder)Dr. Alan Barge(Chief Executive Officer & Co-founder)Dr. Eyal Greenberg(Chief Development Officer & Scientific Co-founder)Prof. Gal Markel(Chief Scientific Officer & Co-founder)Prof. Jacob Schachter(Chief Medical Officer & Co-founder)
Ayala Pharma is associated with pharmaceutical drug candidates including AL102, AL101, and BST-236; the page states that AL102 and AL101 were acquired by Immunome, Inc. in Q1 2024.
Biotech
Co-investorsaMoon
Biond Bio is a clinical-stage biotechnology company developing first-in-class antibody therapies for oncology and immune-mediated diseases, targeting immune evasion mechanisms and pathological pathways.
BiotechHealthtech
Co-investorsDeep Insight
Biosight was a pharmaceutical company that merged with Ayala Pharmaceuticals on October 19, 2023.
Biotech
Co-investorsTrendlines Group
Gamida Cell develops cell therapy treatments designed to expand and enhance cells for therapeutic applications.
BiotechHealthtechLongevityMedical Devices
Nectin Therapeutics develops novel monoclonal antibodies and antibody-drug-conjugates to treat difficult-to-treat cancers by targeting immune evasion mechanisms.
BiotechDeep TechMedical Devices
Co-investorsPeregrine VenturesCancer Focus
Ukko develops immuno-therapeutics for life-threatening food allergies using a computational protein design platform.
AI & Machine LearningBiotechDigital HealthMountain View, US
Anat Binur(Executive Officer, Director)inYanay Ofran(Director)inJudith Weiss Paltiel(PhD, VP Development)in
BoardScott Brady(Director)Samir Kaul(Director)in
Co-investorsKhosla VenturesSanara CapitalWestern Technology InvestmentFall Line CapitalLeaps by BayerPeakBridge VC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AdvaxisExoprotherPharma2B
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.